{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:37Z","timestamp":1793381077372,"version":"4.5.0"},"reference-count":46,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"\n Background<\/jats:title>\n The spectrum of cutaneous immune-related adverse events (cirAEs) has been described, and the occurrence of cirAEs may be associated with improved survival. However, the accuracy of these findings is limited by inconsistent classification.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n This study was designed to determine the type, incidence, and timing of cirAEs and their impacts on survival in cancer patients treated with atezolizumab by using the Medical Dictionary for Regulatory Activities (MedDRA) classification.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The Vivli platform was used to search for randomised controlled trials (RCTs) on atezolizumab. Patients with individual patient data (IPD) were enrolled in the study. Both 1-stage pooled analysis and 2-stage meta-analysis were used to estimate the survival outcomes of the occurrence of cirAEs during atezolizumab therapy, as well as their types, incidences, and timing.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Fifteen RCTs having IPDs of 5870 patients were enrolled in this study. The incidence was 27.5% in this study, with rash\/eruption\/exanthem (83.9%) being the most frequent cirAEs. The earliest types to occur were alopecia. The occurrence of cirAE was an independent protective factor for both overall survival (OS, hazard ratio [HR]=0.40-0.72) and progression-free survival (PFS, HR=0.52-0.84). However, with respect to specific types, urticaria, erythema, alopecia, etc. were found to be independent protective factors for OS, whereas dry skin, purpura, dermatitis\/eczema, etc. were found to be independent protective factors for PFS. Regarding the impact of management and outcomes, cirAE following medical treatment was an independent protective factor for both OS (HR=0.731, 0.622-0.859, P<0.001) and PFS (HR=0.785, 0.699-0.881, P<0.001).<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n No patients treated with Programmed Death-1 (PD-1) or Cytotoxic T-Lymphocyte associated Antigen 4 (CTLA-4) agonists were enrolled.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Atezolizumab-induced cirAEs cover almost all types of dermatological diseases, with varied timing and severity. CirAEs, in general, are linked to improved treatment responses, but different types have different prognostic significance. The treatment of cirAE could influence cancer survival, suggesting the necessity of active management of cirAEs during atezolizumab therapy.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/ijdvl_1043_2025","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:35:06Z","timestamp":1763454906000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and clinical significance of cutaneous immune-related adverse events during atezolizumab therapy: An individual participant data meta-analysis"],"prefix":"10.25259","volume":"0","author":[{"given":"Rentao","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"10.25259\/IJDVL_1043_2025\/ref-1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"10.25259\/IJDVL_1043_2025\/ref-2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41422-020-0343-4","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.25259\/IJDVL_1043_2025\/ref-3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-020-0343-4","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol."},{"key":"10.25259\/IJDVL_1043_2025\/ref-4","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1038\/s41422-020-0343-4","article-title":"Patient-reported outcomes from the phase III Randomized IMmotion151 trial: Atezolizumab plus bevacizumab versus sunitinib in treatment-naive metastatic renal cell carcinoma","volume":"26","author":"Atkins","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.25259\/IJDVL_1043_2025\/ref-5","doi-asserted-by":"publisher","first-page":"e200423","DOI":"10.1038\/s41422-020-0343-4","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.25259\/IJDVL_1043_2025\/ref-6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1043_2025\/ref-7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41422-020-0343-4","article-title":"Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: Using CTCAE and PRO-CTCAE\u00ae to provide two distinct and complementary perspectives","volume":"13","author":"Minasian","year":"2022","journal-title":"Patient Relat Outcome Meas"},{"key":"10.25259\/IJDVL_1043_2025\/ref-8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41422-020-0343-4","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-9","doi-asserted-by":"publisher","first-page":"1071983","DOI":"10.1038\/s41422-020-0343-4","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-10","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41422-020-0343-4","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-11","doi-asserted-by":"publisher","first-page":"9768384","DOI":"10.1038\/s41422-020-0343-4","article-title":"Health data sharing platforms: Serving researchers through provision of access to high-quality data for reuse","volume":"2022","author":"Li","year":"2022","journal-title":"Health Data Sci"},{"key":"10.25259\/IJDVL_1043_2025\/ref-12","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41422-020-0343-4","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"10.25259\/IJDVL_1043_2025\/ref-13","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_1043_2025\/ref-14","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41422-020-0343-4","article-title":"FIR: Efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-Selected Patients With NSCLC","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_1043_2025\/ref-16","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41422-020-0343-4","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-17","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_1043_2025\/ref-18","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_1043_2025\/ref-19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_1043_2025\/ref-20","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1043_2025\/ref-21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-23","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41422-020-0343-4","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1043_2025\/ref-24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41422-020-0343-4","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.25259\/IJDVL_1043_2025\/ref-25","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_1043_2025\/ref-26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41422-020-0343-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/s41422-020-0343-4","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_1043_2025\/ref-28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41422-020-0343-4","article-title":"CTCAE versi\u00f3n 5.0 Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"10.25259\/IJDVL_1043_2025\/ref-29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41422-020-0343-4","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.25259\/IJDVL_1043_2025\/ref-30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41422-020-0343-4","article-title":"Reviewing RECIST in the era of prolonged and targeted therapy","volume":"13","author":"Morgan","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-32","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41422-020-0343-4","article-title":"The spectrum of cutaneous immune-related adverse events in patients with skin of color","volume":"88","author":"Belzer","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41422-020-0343-4","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41422-020-0343-4","article-title":"Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: A multicentre study from the European academy of dermatology and venereology task force of dermatology for cancer patients","volume":"187","author":"Nikolaou","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41422-020-0343-4","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-36","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1038\/s41422-020-0343-4","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41422-020-0343-4","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.25259\/IJDVL_1043_2025\/ref-38","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/s41422-020-0343-4","article-title":"Cutaneous adverse events: A predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-39","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41422-020-0343-4","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-40","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-41","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint blockade and skin toxicity pathogenesis","volume":"142","author":"Ma","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"10.25259\/IJDVL_1043_2025\/ref-43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41422-020-0343-4","article-title":"Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors","volume":"87","author":"Hirotsu","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41422-020-0343-4","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41422-020-0343-4","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41422-020-0343-4","article-title":"Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity","volume":"185","author":"Thompson","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_1043_2025\/ref-47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41422-020-0343-4","article-title":"Dermatology evaluation for cutaneous immune-related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition","volume":"88","author":"Jacoby","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/characteristics-and-clinical-significance-of-cutaneous-immune-related-adverse-events-during-atezolizumab-therapy-an-individual-participant-data-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/characteristics-and-clinical-significance-of-cutaneous-immune-related-adverse-events-during-atezolizumab-therapy-an-individual-participant-data-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:02:21Z","timestamp":1767358941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/characteristics-and-clinical-significance-of-cutaneous-immune-related-adverse-events-during-atezolizumab-therapy-an-individual-participant-data-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":46,"alternative-id":["10.25259\/IJDVL_1043_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1043_2025","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1"}}